ViiV posts positive long-term data for two-drug HIV regimen Dovato
Dovato demonstrated non-inferior efficacy compared to TAF-based regimens
Read More
Tag: Dovato
GSK’s Dovato hits endpoints in late-stage study
In a Phase III study the drug combo was as effective in controlling HIV-1 as a Vemlidy combo.
Read More
ViiV secures EU nod for HIV therapy Dovato
Availability of the two-drug regimen is considered a significant development for people with the condition
Read More
GSK’s HIV drug Dovato gets FDA approval
It marks the first two-drug complete regimen for HIV-infected patients.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
